Fluoxetine pharmacokinetics in pediatric patients

Journal of Clinical Psychopharmacology

Volumn 22, Issue 6, 2002, Pages 568-575

  Wilens, Timothy E ^a   Cohen, Louise ^a   Biederman, Joseph ^a   Abrams, Annah ^a   Neft, Debarah ^a   Faird, Nagy ^b   Sinha, Vikram ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FLUOXETINE; NORFLUOXETINE;

ADOLESCENT; ADULT; AGE; ARTICLE; BODY MASS; BODY SURFACE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; MALE; PEDIATRICS; PHARMACOKINETICS; PRIORITY JOURNAL; STEADY STATE;

ADOLESCENT; CHILD; FEMALE; FLUOXETINE; HUMANS; MALE; MENTAL DISORDERS; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS;

EID: 0036894829     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200212000-00006     Document Type: Article

References (37)

1. Anderson JC, Williams S, McGee R, et al. DSM III disorders in preadolescent children. Prevalence in a large sample from the general population. Arch Gen Psychiatry 1987;44:69-76.
2. Bird HR, Gould MS, Staghezza BM. Patterns of diagnostic comorbidity in a community sample of children aged 9 through 16 years. J Am Acad Child Adolesc Psychiatry 1993;32:361-8.
3. Costello J, Angold A, Burns B, et al. The Great Smoky Mountains Study of Youth: Functional impairment and serious emotional disturbance. Arch Gen Psychiatry 1996;53:1137-43.
4. Fleming JE, Offord DR. Epidemiology of childhood depressive disorders: A critical review. J Am Acad Child Adolesc Psychiatry 1990;29:571-80.
5. Zohar AH. The epidemiology of obsessive compulsive disorder in children and adolescent. In: Child and Adolescent Psychiatric Clinics of North America. 8th Ed. Philadelphia: Saunders, 1999:445-60.
6. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997;54:1031-7.
7. Riddle MA, Scahill L, King RA, et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992;31:1062-9.
8. March J, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive compulsive disorder: A multicenter double-blind placebo controlled study. JAMA 1998;280:1752-6.
9. Gram LF. Fluoxetine. N Engl J Med 1994;331:1354-61.
10. Bergstrom RF, Lemberger L, Farid NA, et al. Clinical pharmacology and pharmacokinetics of fluoxetine: A review. Br J Psychiatry Suppl 1988;3:47-50.
11. Bergstrom RF, Beasley CM Jr, Levy NB, et al. The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine. Int Clin Psychopharmacol 1993; 8:261-6.
12. Levy NB, Blumenfield M, Beasley CM Jr, et al. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. Gen Hosp Psychiatry 1996;18:8-13.
13. Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 2001;40:773-9.
14. Wilson J, Kearns G, Murphy D, et al. Paediatric labelling requirements. Implications for pharmacokinetic studies. Clin Pharmacokinet 1994;26:308-25.
15. von Moltke LL, Greenblatt DJ, Duan SX, et al. Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology (Berl) 1997;132:402-7.
16. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994;26:201-14.
17. Aronoff GR, Bergstrom RF, Pottratz ST, et al. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 1984;36:138-44.
18. Lundmark J, Reis M, Bengtsson F. Serum concentrations of fluoxetine in the clinical treatment setting. Ther Drug Monit 2001;23:139-47.
19. Vozeh S, Steimer J, Rowland M, et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 1996;30:81-93.
20. Sun H, Fadiran EO, Jones CD, et al. Population pharmacokinetics: A regulatory perspective. Clin Pharmacokinet 1999;37:41-58.
21. Markowitz JS, Patrick KS. Pharmaokinetic and pharmacodynamic drug interactions in the treatment of ADHD. Clin Pharmacokinet 2001;40:753-72.
22. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 1992;32:185-209.
23. Belanger B, Davidian M, Giltinan D. The effect of variance estimation on nonlinear calibration inference in immunoassay data. Biometrics 1995;52:158-75.
24. Markowitz JS, Morrison SD, DeVane CL. Drug interactions with psychostimulants. Int Clin Psychopharmacol 1999;14:1-18.
25. DeVane CL, Markowitz JS, Carson SW, et al. Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers. J Clin Psychopharmacol 2000;20:347-9.
26. Beasley CM Jr, Bosomworth JC, Wernicke JF. Fluoxetine: Relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990;26:18-24.
27. Leeder JS, Kearns GL. Pharmacogenetics in pediatrics: Implications for practice. Pediatr Clin North Am 1997;44:55-77.
28. Evans WE, Relling MV, Petros WP, et al. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquinoxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989;45:568-73.
29. Relling MV, Lin JS, Ayers GD, et al. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992;52:643-58.
30. Cohen L, Prince J, Biederman J, et al. Desipramine clearance in children and adolescents: Absence of effect of development and gender. J Am Acad Child Adolesc Psychiatry 1999;38:79-85.
31. Findling RL, Preskorn SH, Marcus RN, et al. Nefazodone pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 2000;39:1008-16.
32. Findling RL, Reed MD, Myers C, et al. Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38:952-9.
33. Alderman J, Wolkow R, Chung M, et al. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: Pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry 1998;37:386-94.
34. Wilens TE, Biederman J, Baldessarini RJ, et al. Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. J Am Acad Child Adolesc Psychiatry 1992;31:691-9.
35. Jatlow PI. Psychotropic drug disposition during development. In: Popper C, ed. Psychiatric Pharmacosciences of Children and Adolescents. Washington: American Psychiatric Press, 1987:29-44.
36. Anonymous. National Institutes of Health Consensus Development Conference statement: Diagnosis and treatment of attentiondeficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 2000;39:182-93.
37. Cohen LG, Prince J, Biederman J, et al. Absence of effect of stimulants on the phamacokinetics of desipramine in children. Pharmacotherapy 1999;19:746-52.